| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000013430 |
| Receipt No. | R000015680 |
| Official scientific title of the study | A phase II study of adjuvant chemotherapy with 5-FU and heparin-based portal infusion chemotherapy followed by TS-1 for patients with resected pancreatic cancer (TOSPAC-02) |
| Date of disclosure of the study information | 2014/03/15 |
| Last modified on | 2018/03/23 (Ver. 12) |
| Basic information | ||
| Official scientific title of the study | A phase II study of adjuvant chemotherapy with 5-FU and heparin-based portal infusion chemotherapy followed by TS-1 for patients with resected pancreatic cancer (TOSPAC-02) | |
| Title of the study (Brief title) | A phase II study of portal infusion chemotherapy followed by TS-1 for resected pancreatic cancer (TOSPAC-02) | |
| Region |
|
|
| Condition | ||
| Condition | Resected pancreatic cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the feasibility and efficacy of adjuvant chemotherapy with 5-FU and heparin-based portal infusion chemotherapy followed by TS-1 for patients with pancratic cancer after surgery |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase II |
| Assessment | |
| Primary outcomes | Disease free survival
Incidence of severe adverse events |
| Key secondary outcomes | Overall survival
Incidence of adverse events Proportion of treatment completion |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Historical |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | With adjuvant chemotherapy of 5-FU and heparin-based portal infusion chemotherapy followed by TS-1 after surgery | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Histologically proven invasive ductal carcinoma of the pancreas
2) Macroscopically curative resection (R0, R1) 3) No history of prior chemotherapy or radiotherapy for pancreatic cancer except pancreatectomy 4) ECOG PS: 0-1 5) Sufficient organ functions before surgery WBC > 4,000/mm3 Neutrophil > 2,000/mm3 Plt > 100,000/mm3 Hb > 9 g/dl AST, ALT < 5 times the upper limit of the normal range Serum creatinine < the upper limit of the normal range 6) Placement of the catheter for portal infusion chemotherapy within the portal vein 7) Written informed consent |
|||
| Key exclusion criteria | 1) Pulmonary fibrosis or interstitial pneumonia
2) Uncontrolled pleural effusion 3) Resection of the distant organ metastasis 4) Active double cancer 5) Active infection 6) History of serious complications related to surgery 7) Active peptic ulcer 8) History of myocardial infarction within three months 9) Severe mental disorder 10) Pregnant or breast feeding 11) Patients judged inappropriate for the study by the physicians |
|||
| Target sample size | 55 | |||
| Research contact person | |
| Name of lead principal investigator | Minoru Kitago |
| Organization | Keio University School of Medicine |
| Division name | Department of Surgery |
| Address | 35, Shinanomachi, Shinjuku-ku, Tokyo |
| TEL | 03-3353-1211 |
| contact@keio-hpbts.jp | |
| Public contact | |
| Name of contact person | Minoru Kitago |
| Organization | Keio University School of Medicine |
| Division name | Department of Surgery |
| Address | 35, Shinanomachi, Shinjuku-ku, Tokyo |
| TEL | 03-3353-1211 |
| Homepage URL | |
| contact@keio-hpbts.jp | |
| Sponsor | |
| Institute | Tokyo Study Group for Pancreatic Cancer (TOSPAC) |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 慶應義塾大学病院(東京都)、川崎市立川崎病院(神奈川県)、北里研究所病医院(東京都)、東京歯科大学市川総合病院(千葉県)
|
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000015680 |